CRD-4730
/ Cardurion
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
December 04, 2025
A Phase 2 Study of CRD-4730 in CPVT
(clinicaltrials.gov)
- P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ventricular Tachycardia
August 18, 2025
A Phase 2 Study of CRD-4730 in CPVT
(clinicaltrials.gov)
- P2 | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Trial completion date: Sep 2026 ➔ Apr 2027 | Initiation date: May 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2026 ➔ Apr 2027
Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Ventricular Tachycardia
July 14, 2025
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2 | N=7 | Terminated | Sponsor: Cardurion Pharmaceuticals, Inc. | N=12 ➔ 7 | Trial completion date: Sep 2025 ➔ May 2025 | Recruiting ➔ Terminated; The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.
Enrollment change • Trial completion date • Trial termination • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2
January 10, 2025
Effectiveness of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ Jul 2025
Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2
October 28, 2024
Effectiveness of Repeat-dose CRD-4730 in Participants with CPVT
(clinicaltrials.gov)
- P2 | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.
New P2 trial • Cardiovascular • Ventricular Tachycardia
November 27, 2023
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Phase classification: P2a ➔ P2
Enrollment open • Phase classification • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2
August 22, 2023
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2a | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.
New P2a trial • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2
1 to 7
Of
7
Go to page
1